MANGALAM DRUGS AND ORGANICS Financial Statement Analysis
|
||
|
The Revenues of MANGALAM DRUGS AND ORGANICS have increased by 17.25% YoY .
The Earnings Per Share (EPS) of MANGALAM DRUGS AND ORGANICS has decreased by -93.56 % YoY. |
||
| REVENUES |
| OPERATING MARGIN |
| PROFIT AFTER TAX |
| EPS |
| ROCE |
MANGALAM DRUGS AND ORGANICS Last 5 Annual Financial Results
[BOM: 532637|NSE : MANGALAM]
| Standalone | Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 |
|---|---|---|---|---|---|
| Revenues | ₹451 Cr | ₹385 Cr | ₹282 Cr | ₹228 Cr | ₹279 Cr |
| Expenses | ₹402 Cr | ₹327 Cr | ₹259 Cr | ₹218 Cr | ₹233 Cr |
| Operating Profit (Excl OI) | ₹49 Cr | ₹58 Cr | ₹24 Cr | ₹9.68 Cr | ₹47 Cr |
| Other Income | ₹0.09 Cr | ₹0.00 Cr | ₹1.18 Cr | ₹0.32 Cr | ₹0.84 Cr |
| Interest | ₹11 Cr | ₹9.33 Cr | ₹10 Cr | ₹8.65 Cr | ₹12 Cr |
| Depreciation | ₹10 Cr | ₹9.18 Cr | ₹8.22 Cr | ₹7.09 Cr | ₹6.57 Cr |
| Profit Before Tax | ₹28 Cr | ₹40 Cr | ₹6.25 Cr | ₹-5.74 Cr | ₹29 Cr |
| Profit After Tax | ₹20 Cr | ₹28 Cr | ₹8.25 Cr | ₹-8.03 Cr | ₹20 Cr |
| Consolidated Net Profit | ₹20 Cr | ₹28 Cr | ₹8.25 Cr | ₹-8.12 Cr | ₹20 Cr |
| Earnings Per Share (Rs) | ₹0.80 | ₹12.42 | ₹17.67 | ₹5.21 | ₹-5.07 |
| PAT Margin (%) | 0.34 | 4.36 | 7.27 | 2.64 | -3.10 |
| ROE(%) | 0.84 | 13.97 | 23.83 | 8.27 | -8.05 |
| ROCE(%) | 6.56 | 18.34 | 28.01 | 10.66 | 1.76 |
| Total Debt/Equity(x) | 0.49 | 0.52 | 0.49 | 0.48 | 0.66 |
Key Financials |
||
| Market Cap | : | ₹ 159.2 Cr |
| Revenue (TTM) | : | ₹ 357.5 Cr |
| Net Profit(TTM) | : | ₹ -17.0 Cr |
| EPS (TTM) | : | ₹ -10.7 |
| P/E (TTM) | : | - |
| Industry Peers & Returns | 1W | 1M | 1Y |
| MANGALAM DRUGS AND ORGANICS | 1.1% | 2.7% | -10.1% |
| SUN PHARMACEUTICAL INDUSTRIES | -0.1% | -2.8% | 50.3% |
| CIPLA | 4.5% | -3.1% | 52.8% |
| DR REDDYS LABORATORIES | 4.6% | 1.4% | 22.2% |
| ZYDUS LIFESCIENCES | 3.1% | -4.1% | 80.4% |
| DIVIS LABORATORIES | 4.7% | 10.8% | 18.1% |
| MANKIND PHARMA | 2.7% | 12.4% | NA |
| TORRENT PHARMACEUTICALS | 6.1% | 5.3% | 66.2% |
| LUPIN | 3.1% | -1.1% | 127.4% |
MANGALAM DRUGS AND ORGANICS Revenues
[BOM: 532637|NSE : MANGALAM]
| Y-o-Y | 17.25 % |
| 5 Yr CAGR | 12.72 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2023 | ₹451 Cr | 17.25 | |
| Mar2022 | ₹385 Cr | 36.25 | |
| Mar2021 | ₹282 Cr | 24.07 | |
| Mar2020 | ₹228 Cr | -18.54 | |
| Mar2019 | ₹279 Cr | - | |
MANGALAM DRUGS AND ORGANICS Operating Profit
[BOM: 532637|NSE : MANGALAM]
| Y-o-Y | -15.45 % |
| 5 Yr CAGR | 1.15 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2023 | ₹49 Cr | -15.45 | |
| Mar2022 | ₹58 Cr | 144.89 | |
| Mar2021 | ₹24 Cr | 144.74 | |
| Mar2020 | ₹9.68 Cr | -79.34 | |
| Mar2019 | ₹47 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | -27.85 % |
| 5 Yr CAGR | -10.25 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2023 | 10.88% | -27.85 | |
| Mar2022 | 15.08% | 79.74 | |
| Mar2021 | 8.39% | 97.41 | |
| Mar2020 | 4.25% | -74.66 | |
| Mar2019 | 16.77% | - | |
MANGALAM DRUGS AND ORGANICS Profit After Tax
[BOM: 532637|NSE : MANGALAM]
| Y-o-Y | -29.72 % |
| 5 Yr CAGR | -0.29 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2023 | ₹20 Cr | -29.72 | |
| Mar2022 | ₹28 Cr | 238.92 | |
| Mar2021 | ₹8.25 Cr | Positive | |
| Mar2020 | ₹-8.12 Cr | Negative | |
| Mar2019 | ₹20 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | -92.20 % |
| 5 Yr CAGR | Positive |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2023 | 0.34 % | -92.20 | |
| Mar2022 | 4.36 % | -40.03 | |
| Mar2021 | 7.27 % | 175.38 | |
| Mar2020 | 2.64 % | Positive | |
| Mar2019 | -3.1 % | - | |
MANGALAM DRUGS AND ORGANICS Earnings Per Share (EPS)
[BOM: 532637|NSE : MANGALAM]
| Y-o-Y | -93.56 % |
| 5 Yr CAGR | Positive |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2023 | ₹0.80 | -93.56 | |
| Mar2022 | ₹12 | -29.71 | |
| Mar2021 | ₹18 | 239.16 | |
| Mar2020 | ₹5.21 | Positive | |
| Mar2019 | ₹-5.07 | - | |
MANGALAM DRUGS AND ORGANICS Return on Capital Employed (ROCE)
[BOM: 532637|NSE : MANGALAM]
| Y-o-Y | -64.23 % |
| 5 Yr CAGR | 38.95 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2023 | 6.56% | -64.23 | |
| Mar2022 | 18.34% | -34.52 | |
| Mar2021 | 28.01% | 162.76 | |
| Mar2020 | 10.66% | 505.68 | |
| Mar2019 | 1.76% | - | |
MANGALAM DRUGS AND ORGANICS Share Price vs Sensex
| Current Share Price | : | ₹100.8 |
| Current MarketCap | : | ₹ 159.2 Cr |
| Updated EOD on | : | Apr 25,2024 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| MANGALAM DRUGS AND ORGANICS | 1.1% |
2.7% |
-10.1% |
| SENSEX | 1.3% |
2.6% |
24% |
MANGALAM DRUGS AND ORGANICS related INDICES
No BSE index found!
No NSE index found
You may also like the below Video Courses
FAQ about MANGALAM DRUGS AND ORGANICS Financials
How the annual revenues of MANGALAM DRUGS AND ORGANICS have changed ?
The Revenues of MANGALAM DRUGS AND ORGANICS have increased by 17.25% YoY .
How the Earnings per Share (EPS) of MANGALAM DRUGS AND ORGANICS have changed?
The Earnings Per Share (EPS) of MANGALAM DRUGS AND ORGANICS has decreased by -93.56 % YoY .
Check out Intrinsic Value of Peers of MANGALAM DRUGS AND ORGANICS
Compare Stock Analytics of Peers of MANGALAM DRUGS AND ORGANICS
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
